APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumor Necrosis Factor Inhibitors Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Tumor Necrosis Factor Inhibitors Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025196 pages

Choose your research edition.

Industry ResearchTumor Necrosis Factor Inhibitors Drug Industry Research Report 2026147 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Necrosis Factor Inhibitors Drug Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Tumor Necrosis Factor Inhibitors Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Necrosis Factor Inhibitors Drug Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Necrosis Factor Inhibitors Drug Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Tumor Necrosis Factor Inhibitors Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Tumor Necrosis Factor Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tumor Necrosis Factor Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumor Necrosis Factor Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Tumor Necrosis Factor Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tumor Necrosis Factor Inhibitors Drug include Sandoz, Novartis, GlaxoSmithKline, Zydus Cadila, UCB, Tsumura, Toyama Chemical, Simcere Pharmaceutical and Shanghai Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tumor Necrosis Factor Inhibitors Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tumor Necrosis Factor Inhibitors Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tumor Necrosis Factor Inhibitors Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tumor Necrosis Factor Inhibitors Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Tumor Necrosis Factor Inhibitors Drug Segment by Company

Sandoz

Novartis

GlaxoSmithKline

Zydus Cadila

UCB

Tsumura

Toyama Chemical

Simcere Pharmaceutical

Shanghai Pharmaceuticals

Shanghai CP Guojian Pharmaceutical

Sanofi-Aventis

Samsung Bioepis

Reliance Life Sciences

PROBIOMED

Momenta Pharmaceuticals

MedImmune

LG Life Sciences

LEO Pharma

Janssen Biotech

Intas Pharmaceuticals

HanAll Biopharma

EPIRUS Biopharmaceuticals

Dexa Medica

Delenex Therapeutics

Celltrion

Celgene Corporation

CASI Pharmaceuticals

Bionovis

AryoGen Biopharma

Apogenix

Tumor Necrosis Factor Inhibitors Drug Segment by Type

Enbrel (Etanercept)

Simponi (Golimumab)

Cimzia (Certolizumab Pegol)

Remicade (Infliximab)

Otezla (Apremilast)

Humira ( Adalimumab)

Tumor Necrosis Factor Inhibitors Drug Segment by Application

Clinic

Hospital

Others

Tumor Necrosis Factor Inhibitors Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Inhibitors Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Inhibitors Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Inhibitors Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tumor Necrosis Factor Inhibitors Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Tumor Necrosis Factor Inhibitors Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Tumor Necrosis Factor Inhibitors Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Tumor Necrosis Factor Inhibitors Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Tumor Necrosis Factor Inhibitors Drug Industry Trends Table 2. Tumor Necrosis Factor Inhibitors Drug Industry Drivers Table 3. Tumor Necrosis Factor Inhibitors Drug Industry Opportunities and Challenges Table 4. Tumor Necrosis Factor Inhibitors Drug Industry Restraints Table 5. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Tumor Necrosis Factor Inhibitors Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Manufacturers Table 9. Global Tumor Necrosis Factor Inhibitors Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Tumor Necrosis Factor Inhibitors Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Tumor Necrosis Factor Inhibitors Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Tumor Necrosis Factor Inhibitors Drug Manufacturers, Product Type & Application Table 13. Global Tumor Necrosis Factor Inhibitors Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Tumor Necrosis Factor Inhibitors Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Enbrel (Etanercept) Table 17. Major Manufacturers of Simponi (Golimumab) Table 18. Major Manufacturers of Cimzia (Certolizumab Pegol) Table 19. Major Manufacturers of Remicade (Infliximab) Table 20. Major Manufacturers of Otezla (Apremilast) Table 21. Major Manufacturers of Humira ( Adalimumab) Table 22. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2026) & (k units) Table 24. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2027-2032) & (k units) Table 25. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2021-2026) Table 26. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2027-2032) Table 27. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 28. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2021-2026) & (k units) Table 29. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2027-2032) & (k units) Table 30. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2021-2026) Table 31. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of Others Table 35. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2026) & (k units) Table 37. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2027-2032) & (k units) Table 38. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2021-2026) Table 39. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2027-2032) Table 40. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 41. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2021-2026) & (k units) Table 42. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2027-2032) & (k units) Table 43. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2021-2026) Table 44. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2027-2032) Table 45. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2021-2026) & (k units) Table 47. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2021-2026) Table 48. Global Tumor Necrosis Factor Inhibitors Drug Sales Forecasted by Region (2027-2032) & (k units) Table 49. Global Tumor Necrosis Factor Inhibitors Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026) & (k units) Table 52. North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2027-2032) & (k units) Table 53. Europe Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026) & (k units) Table 55. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2027-2032) & (k units) Table 56. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026) & (k units) Table 58. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Country (2027-2032) & (k units) Table 59. South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 60. South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026) & (k units) Table 61. South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2027-2032) & (k units) Table 62. Global Tumor Necrosis Factor Inhibitors Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2021-2026) Table 66. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2027-2032) Table 67. Sandoz Company Information Table 68. Sandoz Business Overview Table 69. Sandoz Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Sandoz Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 71. Sandoz Recent Development Table 72. Novartis Company Information Table 73. Novartis Business Overview Table 74. Novartis Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Novartis Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 76. Novartis Recent Development Table 77. GlaxoSmithKline Company Information Table 78. GlaxoSmithKline Business Overview Table 79. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 81. GlaxoSmithKline Recent Development Table 82. Zydus Cadila Company Information Table 83. Zydus Cadila Business Overview Table 84. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 86. Zydus Cadila Recent Development Table 87. UCB Company Information Table 88. UCB Business Overview Table 89. UCB Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. UCB Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 91. UCB Recent Development Table 92. Tsumura Company Information Table 93. Tsumura Business Overview Table 94. Tsumura Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Tsumura Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 96. Tsumura Recent Development Table 97. Toyama Chemical Company Information Table 98. Toyama Chemical Business Overview Table 99. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 101. Toyama Chemical Recent Development Table 102. Simcere Pharmaceutical Company Information Table 103. Simcere Pharmaceutical Business Overview Table 104. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 106. Simcere Pharmaceutical Recent Development Table 107. Shanghai Pharmaceuticals Company Information Table 108. Shanghai Pharmaceuticals Business Overview Table 109. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 111. Shanghai Pharmaceuticals Recent Development Table 112. Shanghai CP Guojian Pharmaceutical Company Information Table 113. Shanghai CP Guojian Pharmaceutical Business Overview Table 114. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 116. Shanghai CP Guojian Pharmaceutical Recent Development Table 117. Sanofi-Aventis Company Information Table 118. Sanofi-Aventis Business Overview Table 119. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 121. Sanofi-Aventis Recent Development Table 122. Samsung Bioepis Company Information Table 123. Samsung Bioepis Business Overview Table 124. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 126. Samsung Bioepis Recent Development Table 127. Reliance Life Sciences Company Information Table 128. Reliance Life Sciences Business Overview Table 129. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 131. Reliance Life Sciences Recent Development Table 132. PROBIOMED Company Information Table 133. PROBIOMED Business Overview Table 134. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 136. PROBIOMED Recent Development Table 137. Momenta Pharmaceuticals Company Information Table 138. Momenta Pharmaceuticals Business Overview Table 139. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 141. Momenta Pharmaceuticals Recent Development Table 142. MedImmune Company Information Table 143. MedImmune Business Overview Table 144. MedImmune Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. MedImmune Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 146. MedImmune Recent Development Table 147. LG Life Sciences Company Information Table 148. LG Life Sciences Business Overview Table 149. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 151. LG Life Sciences Recent Development Table 152. LEO Pharma Company Information Table 153. LEO Pharma Business Overview Table 154. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 155. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 156. LEO Pharma Recent Development Table 157. Janssen Biotech Company Information Table 158. Janssen Biotech Business Overview Table 159. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 160. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 161. Janssen Biotech Recent Development Table 162. Intas Pharmaceuticals Company Information Table 163. Intas Pharmaceuticals Business Overview Table 164. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 165. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 166. Intas Pharmaceuticals Recent Development Table 167. HanAll Biopharma Company Information Table 168. HanAll Biopharma Business Overview Table 169. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 170. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 171. HanAll Biopharma Recent Development Table 172. EPIRUS Biopharmaceuticals Company Information Table 173. EPIRUS Biopharmaceuticals Business Overview Table 174. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 175. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 176. EPIRUS Biopharmaceuticals Recent Development Table 177. Dexa Medica Company Information Table 178. Dexa Medica Business Overview Table 179. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 180. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 181. Dexa Medica Recent Development Table 182. Delenex Therapeutics Company Information Table 183. Delenex Therapeutics Business Overview Table 184. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 185. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 186. Delenex Therapeutics Recent Development Table 187. Celltrion Company Information Table 188. Celltrion Business Overview Table 189. Celltrion Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 190. Celltrion Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 191. Celltrion Recent Development Table 192. Celgene Corporation Company Information Table 193. Celgene Corporation Business Overview Table 194. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 195. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 196. Celgene Corporation Recent Development Table 197. CASI Pharmaceuticals Company Information Table 198. CASI Pharmaceuticals Business Overview Table 199. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 200. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 201. CASI Pharmaceuticals Recent Development Table 202. Bionovis Company Information Table 203. Bionovis Business Overview Table 204. Bionovis Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 205. Bionovis Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 206. Bionovis Recent Development Table 207. AryoGen Biopharma Company Information Table 208. AryoGen Biopharma Business Overview Table 209. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 210. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 211. AryoGen Biopharma Recent Development Table 212. Apogenix Company Information Table 213. Apogenix Business Overview Table 214. Apogenix Tumor Necrosis Factor Inhibitors Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 215. Apogenix Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 216. Apogenix Recent Development Table 217. Key Raw Materials Table 218. Raw Materials Key Suppliers Table 219. Tumor Necrosis Factor Inhibitors Drug Distributors List Table 220. Tumor Necrosis Factor Inhibitors Drug Customers List Table 221. Research Programs/Design for This Report Table 222. Authors List of This Report Table 223. Secondary Sources Table 224. Primary Sources List of Figures Figure 1. Tumor Necrosis Factor Inhibitors Drug Product Image Figure 2. Global Tumor Necrosis Factor Inhibitors Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tumor Necrosis Factor Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Tumor Necrosis Factor Inhibitors Drug Sales (2021-2032) & (k units) Figure 5. Global Tumor Necrosis Factor Inhibitors Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Tumor Necrosis Factor Inhibitors Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Enbrel (Etanercept) Image Figure 9. Simponi (Golimumab) Image Figure 10. Cimzia (Certolizumab Pegol) Image Figure 11. Remicade (Infliximab) Image Figure 12. Otezla (Apremilast) Image Figure 13. Humira ( Adalimumab) Image Figure 14. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2021-2032) Figure 17. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 18. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Others Image Figure 23. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2021-2032) Figure 26. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 30. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 32. Canada Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. Mexico Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. France Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. U.K. Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. Italy Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Netherlands Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2021-2032) Figure 43. China Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. Japan Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. South Korea Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. India Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. Australia Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. South Africa Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. Saudi Arabia Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Turkey Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Argentina Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 56. UAE Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 57. Egypt Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 58. Chile Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2032) & (k units) Figure 59. Global Tumor Necrosis Factor Inhibitors Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Tumor Necrosis Factor Inhibitors Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Tumor Necrosis Factor Inhibitors Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Tumor Necrosis Factor Inhibitors Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Tumor Necrosis Factor Inhibitors Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Tumor Necrosis Factor Inhibitors Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Enbrel (Etanercept)
  • Simponi (Golimumab)
  • Cimzia (Certolizumab Pegol)
  • Remicade (Infliximab)
  • Otezla (Apremilast)
  • Humira ( Adalimumab)
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Sandoz
  • Novartis
  • GlaxoSmithKline
  • Zydus Cadila
  • UCB
  • Tsumura
  • Toyama Chemical
  • Simcere Pharmaceutical
  • Shanghai Pharmaceuticals
  • Shanghai CP Guojian Pharmaceutical
  • Sanofi-Aventis
  • Samsung Bioepis
  • Reliance Life Sciences
  • PROBIOMED
  • Momenta Pharmaceuticals
  • MedImmune
  • LG Life Sciences
  • LEO Pharma
  • Janssen Biotech
  • Intas Pharmaceuticals
  • HanAll Biopharma
  • EPIRUS Biopharmaceuticals
  • Dexa Medica
  • Delenex Therapeutics
  • Celltrion
  • Celgene Corporation
  • CASI Pharmaceuticals
  • Bionovis
  • AryoGen Biopharma
  • Apogenix

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tumor Necrosis Factor Inhibitors Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tumor Necrosis Factor Inhibitors Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Tumor Necrosis Factor Inhibitors Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Tumor Necrosis Factor Inhibitors Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Tumor Necrosis Factor Inhibitors Drug Market Dynamics
  1. 2.1 Tumor Necrosis Factor Inhibitors Drug Industry Trends
  2. 2.2 Tumor Necrosis Factor Inhibitors Drug Industry Drivers
  3. 2.3 Tumor Necrosis Factor Inhibitors Drug Industry Opportunities and Challenges
  4. 2.4 Tumor Necrosis Factor Inhibitors Drug Industry Restraints
3 Tumor Necrosis Factor Inhibitors Drug Market by Manufacturers
  1. 3.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Tumor Necrosis Factor Inhibitors Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Tumor Necrosis Factor Inhibitors Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Tumor Necrosis Factor Inhibitors Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Tumor Necrosis Factor Inhibitors Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Tumor Necrosis Factor Inhibitors Drug Manufacturers, Product Type & Application
  7. 3.7 Global Tumor Necrosis Factor Inhibitors Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Tumor Necrosis Factor Inhibitors Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Tumor Necrosis Factor Inhibitors Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Tumor Necrosis Factor Inhibitors Drug Tier 1, Tier 2, and Tier 3
4 Tumor Necrosis Factor Inhibitors Drug Market by Type
  1. 4.1 Tumor Necrosis Factor Inhibitors Drug Type Introduction
  2. 4.1.1 Enbrel (Etanercept)
  3. 4.1.2 Simponi (Golimumab)
  4. 4.1.3 Cimzia (Certolizumab Pegol)
  5. 4.1.4 Remicade (Infliximab)
  6. 4.1.5 Otezla (Apremilast)
  7. 4.1.6 Humira ( Adalimumab)
  8. 4.2 Global Tumor Necrosis Factor Inhibitors Drug Sales by Type
  9. 4.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2032)
  11. 4.2.3 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2021-2032)
  12. 4.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type
  13. 4.3.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2021-2032)
  15. 4.3.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2021-2032)
5 Tumor Necrosis Factor Inhibitors Drug Market by Application
  1. 5.1 Tumor Necrosis Factor Inhibitors Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Tumor Necrosis Factor Inhibitors Drug Sales by Application
  6. 5.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application
  10. 5.3.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2021-2032)
6 Global Tumor Necrosis Factor Inhibitors Drug Sales by Region
  1. 6.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region
  1. 7.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region
  2. 7.1.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Tumor Necrosis Factor Inhibitors Drug Revenue (2021-2032)
  8. 7.2.2 North America Tumor Necrosis Factor Inhibitors Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Tumor Necrosis Factor Inhibitors Drug Revenue (2021-2032)
  11. 7.3.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sandoz
  2. 8.1.1 Sandoz Company Information
  3. 8.1.2 Sandoz Business Overview
  4. 8.1.3 Sandoz Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sandoz Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  6. 8.1.5 Sandoz Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 GlaxoSmithKline
  14. 8.3.1 GlaxoSmithKline Company Information
  15. 8.3.2 GlaxoSmithKline Business Overview
  16. 8.3.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  18. 8.3.5 GlaxoSmithKline Recent Developments
  19. 8.4 Zydus Cadila
  20. 8.4.1 Zydus Cadila Company Information
  21. 8.4.2 Zydus Cadila Business Overview
  22. 8.4.3 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  24. 8.4.5 Zydus Cadila Recent Developments
  25. 8.5 UCB
  26. 8.5.1 UCB Company Information
  27. 8.5.2 UCB Business Overview
  28. 8.5.3 UCB Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 UCB Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  30. 8.5.5 UCB Recent Developments
  31. 8.6 Tsumura
  32. 8.6.1 Tsumura Company Information
  33. 8.6.2 Tsumura Business Overview
  34. 8.6.3 Tsumura Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Tsumura Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  36. 8.6.5 Tsumura Recent Developments
  37. 8.7 Toyama Chemical
  38. 8.7.1 Toyama Chemical Company Information
  39. 8.7.2 Toyama Chemical Business Overview
  40. 8.7.3 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  42. 8.7.5 Toyama Chemical Recent Developments
  43. 8.8 Simcere Pharmaceutical
  44. 8.8.1 Simcere Pharmaceutical Company Information
  45. 8.8.2 Simcere Pharmaceutical Business Overview
  46. 8.8.3 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  48. 8.8.5 Simcere Pharmaceutical Recent Developments
  49. 8.9 Shanghai Pharmaceuticals
  50. 8.9.1 Shanghai Pharmaceuticals Company Information
  51. 8.9.2 Shanghai Pharmaceuticals Business Overview
  52. 8.9.3 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  54. 8.9.5 Shanghai Pharmaceuticals Recent Developments
  55. 8.10 Shanghai CP Guojian Pharmaceutical
  56. 8.10.1 Shanghai CP Guojian Pharmaceutical Company Information
  57. 8.10.2 Shanghai CP Guojian Pharmaceutical Business Overview
  58. 8.10.3 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  60. 8.10.5 Shanghai CP Guojian Pharmaceutical Recent Developments
  61. 8.11 Sanofi-Aventis
  62. 8.11.1 Sanofi-Aventis Company Information
  63. 8.11.2 Sanofi-Aventis Business Overview
  64. 8.11.3 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  66. 8.11.5 Sanofi-Aventis Recent Developments
  67. 8.12 Samsung Bioepis
  68. 8.12.1 Samsung Bioepis Company Information
  69. 8.12.2 Samsung Bioepis Business Overview
  70. 8.12.3 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  72. 8.12.5 Samsung Bioepis Recent Developments
  73. 8.13 Reliance Life Sciences
  74. 8.13.1 Reliance Life Sciences Company Information
  75. 8.13.2 Reliance Life Sciences Business Overview
  76. 8.13.3 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  78. 8.13.5 Reliance Life Sciences Recent Developments
  79. 8.14 PROBIOMED
  80. 8.14.1 PROBIOMED Company Information
  81. 8.14.2 PROBIOMED Business Overview
  82. 8.14.3 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  84. 8.14.5 PROBIOMED Recent Developments
  85. 8.15 Momenta Pharmaceuticals
  86. 8.15.1 Momenta Pharmaceuticals Company Information
  87. 8.15.2 Momenta Pharmaceuticals Business Overview
  88. 8.15.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  90. 8.15.5 Momenta Pharmaceuticals Recent Developments
  91. 8.16 MedImmune
  92. 8.16.1 MedImmune Company Information
  93. 8.16.2 MedImmune Business Overview
  94. 8.16.3 MedImmune Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 MedImmune Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  96. 8.16.5 MedImmune Recent Developments
  97. 8.17 LG Life Sciences
  98. 8.17.1 LG Life Sciences Company Information
  99. 8.17.2 LG Life Sciences Business Overview
  100. 8.17.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  102. 8.17.5 LG Life Sciences Recent Developments
  103. 8.18 LEO Pharma
  104. 8.18.1 LEO Pharma Company Information
  105. 8.18.2 LEO Pharma Business Overview
  106. 8.18.3 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  108. 8.18.5 LEO Pharma Recent Developments
  109. 8.19 Janssen Biotech
  110. 8.19.1 Janssen Biotech Company Information
  111. 8.19.2 Janssen Biotech Business Overview
  112. 8.19.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  114. 8.19.5 Janssen Biotech Recent Developments
  115. 8.20 Intas Pharmaceuticals
  116. 8.20.1 Intas Pharmaceuticals Company Information
  117. 8.20.2 Intas Pharmaceuticals Business Overview
  118. 8.20.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  120. 8.20.5 Intas Pharmaceuticals Recent Developments
  121. 8.21 HanAll Biopharma
  122. 8.21.1 HanAll Biopharma Company Information
  123. 8.21.2 HanAll Biopharma Business Overview
  124. 8.21.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  126. 8.21.5 HanAll Biopharma Recent Developments
  127. 8.22 EPIRUS Biopharmaceuticals
  128. 8.22.1 EPIRUS Biopharmaceuticals Company Information
  129. 8.22.2 EPIRUS Biopharmaceuticals Business Overview
  130. 8.22.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  132. 8.22.5 EPIRUS Biopharmaceuticals Recent Developments
  133. 8.23 Dexa Medica
  134. 8.23.1 Dexa Medica Company Information
  135. 8.23.2 Dexa Medica Business Overview
  136. 8.23.3 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  138. 8.23.5 Dexa Medica Recent Developments
  139. 8.24 Delenex Therapeutics
  140. 8.24.1 Delenex Therapeutics Company Information
  141. 8.24.2 Delenex Therapeutics Business Overview
  142. 8.24.3 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  144. 8.24.5 Delenex Therapeutics Recent Developments
  145. 8.25 Celltrion
  146. 8.25.1 Celltrion Company Information
  147. 8.25.2 Celltrion Business Overview
  148. 8.25.3 Celltrion Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Celltrion Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  150. 8.25.5 Celltrion Recent Developments
  151. 8.26 Celgene Corporation
  152. 8.26.1 Celgene Corporation Company Information
  153. 8.26.2 Celgene Corporation Business Overview
  154. 8.26.3 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  156. 8.26.5 Celgene Corporation Recent Developments
  157. 8.27 CASI Pharmaceuticals
  158. 8.27.1 CASI Pharmaceuticals Company Information
  159. 8.27.2 CASI Pharmaceuticals Business Overview
  160. 8.27.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  161. 8.27.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  162. 8.27.5 CASI Pharmaceuticals Recent Developments
  163. 8.28 Bionovis
  164. 8.28.1 Bionovis Company Information
  165. 8.28.2 Bionovis Business Overview
  166. 8.28.3 Bionovis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  167. 8.28.4 Bionovis Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  168. 8.28.5 Bionovis Recent Developments
  169. 8.29 AryoGen Biopharma
  170. 8.29.1 AryoGen Biopharma Company Information
  171. 8.29.2 AryoGen Biopharma Business Overview
  172. 8.29.3 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  173. 8.29.4 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  174. 8.29.5 AryoGen Biopharma Recent Developments
  175. 8.30 Apogenix
  176. 8.30.1 Apogenix Company Information
  177. 8.30.2 Apogenix Business Overview
  178. 8.30.3 Apogenix Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  179. 8.30.4 Apogenix Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  180. 8.30.5 Apogenix Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tumor Necrosis Factor Inhibitors Drug Value Chain Analysis
  2. 9.1.1 Tumor Necrosis Factor Inhibitors Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tumor Necrosis Factor Inhibitors Drug Production Mode & Process
  6. 9.2 Tumor Necrosis Factor Inhibitors Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tumor Necrosis Factor Inhibitors Drug Distributors
  9. 9.2.3 Tumor Necrosis Factor Inhibitors Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst